The value of the steroid receptor status in the management of endometrial cancer has recently been reviewed (Soutter & Leake, 1987) .
Summary Both soluble and nuclear oestrogen receptors have been measured in at least two separate sections from 72 endometrial. cancers and 12 normal endometria. Concentration of oestrogen receptor is shown to be, in our hands, more meaningful when expressed per unit DNA than per unit protein, whether for soluble or nuclear receptor. Endometrial cancer cells from the central part of the tumour are shown to be receptor negative more frequently than those from peripheral tumour. Thus, in large cancers, biopsies from different areas are required before a tumour can be correctly designated as receptor positive, heterogeneous or receptor negative. The intratumoral variation of receptor status may relate to poor prognosis, since patients with homogeneous receptor-positive disease survive significantly longer than those with tumours showing either heterogeneous distribution of receptor or homogeneous absence of receptor. Intratumoral variation in receptor status is found to be more common in the group of patients who are within 7 years of their menopause, than in older patients.
In Sicily, the incidence of endometrial cancer is increasing. Standardized mortality rate, per 100,000 women, was 9.66 for endometrial cancer (Cislaghi et al., 1978) . However, this rate is thought to be an underestimate (Castagnetta et al., 1980) . Further, endometrial cancer clinics in Palermo have recently seen a rapid increase in new cases. For this reason, better indices of prognosis and therapy selection are required. The relative frequency of locally advanced disease in Sicily provides adequate tissue for an appropriate study.
The value of the steroid receptor status in the management of endometrial cancer has recently been reviewed (Soutter & Leake, 1987) .
The first studies of oestrogen receptor content (in breast cancer) were confined to the soluble fraction (Jensen et al., 1973; Mass et al., 1975) . However, a significant proportion of tumours may contain non-functional receptor in the soluble fraction (Laing et al., 1977; Spelsberg & BoydLeinen, 1980) . Improved prediction of response to endocrine therapy has been achieved through measuring nuclear oestrogen receptor (Barnes et al., 1979; Hahnel et al., 1980; Leake et al., 1981a) , progesterone receptor (Bloom et al., 1980; Hawkins et al., 1980; Osborne et al., 1980) a product of oestrogen action, oestrogen-induced enzyme activity (Duffy & O'Connell, 1981) and oestrogen-induced protein secretion (Veith et al., 1983) . We have selected nuclear oestrogen receptor because this assay is relatively easy, oestrogen nuclear receptor is relatively stable and the amount of tissue needed is relatively small (Leake et al., 1981a) .
In this paper, we report the measurement of soluble and nuclear oestrogen receptor content of biopsies from both the centre and the edge of locally advanced endometrial cancers. Evidence is presented that the results are best expressed relative to the DNA content of the original suspension. Using this approach, we have examined the significance of intratumoral variation of receptor content in relation to the subsequent behaviour of the disease.
Materials and methods

Patients
Seventy-two patients were included in the study. All (Leake et al., 1979; Crawford et al., 1984) . The molecular form of the receptor, as determined by sucrose density gradient analysis, is also stable under these storage conditions for 60-90 days (Crawford et al., 1984 Further purification of the nuclear pellet by differential centrifugation through sucrose (final layer was 2.4M sucrose) did not alter receptor content per unit DNA.
Receptor measurement Incubation of either the cytosol or nuclear pellet with 3H-oestradiol (+ 100-fold excess diethylstilboestrol as competitor) was carried out at seven concentrations in the range 10 -10-9 M. All tubes were incubated at 4°C for 18 h or 20°C for 2 h, both conditions give similar receptor content (Love et al., 1983) .
Unbound steroid was removed from the cytosol (DCC) and nuclear fractions (filtration through Whatman GF/C discs) as previously described (Leake, 1980) . Results were analysed by the method of Scatchard using a simple computer programme (written for the Olivetti M20). Receptor content was only reported as positive if at least five points could be used to determine a 'best fit' line and if the dissociation constant (Kd) lay in the range 5 x 10-"-1 5 x 10-10 M. Intra-assay variation was within 5% (six separate samples) and inter-assay variation within 12% (ten separate assays) using lyophilized quality control samples of human myometrium and endometrial cancer.
Protein and DNA content were determined by the methods of Lowry (Lowry et al., 1951) and Burton (as modified by Katzenellenbogen and Leake, 1974) , respectively.
Results
Expression of receptor concentration Quantitative data on receptor content of breast and endometrial tumours varies considerably between laboratories associated with lower cellularity than those which had both receptor positive and receptor negative components. As reported previously (Castagnetta et al., 1983) , the proportion of grade III tumours is higher in Sicily than elsewhere.
Receptor content
The mean receptor content of the 56 receptor positive samples taken from the edge of each tumour is shown in Table I . Relative receptor content of a small group of histologically normal endometrium is also shown. The mean concentration of receptor in either soluble or nuclear fraction was very similar to that of normal secretory endometrium, whether expressed per unit protein or DNA. For review of the change in receptor content of the normal endometrium during the menstrual cycle (Soutter & Leake, 1987 (--) . Using this classification, receptor status of tumours from the 72 patients can be summarised as shown in Figure  1 . The data indicate that loss of receptor from one fraction (+ -) is more common in the early post-menopausal group (7 out of 19; 37%) than in the late menopausal group (5 out of 45; 11%). This difference is statistically significant (X2test: 0.05> P> 0.025). Table II shows the mean data for all receptor positive biopsies taken from either the periphery or the more central (presumably older) part of the tumour for the 51 patients in the follow-up study (see later). The concentrations are similar to those previously reported for locally advanced endometrial cancer (Billiat et al., 1982) . Soluble receptor was found in 51% of biopsies from the central portion (26 out of 51) and in 67% from the periphery (34 out of 51). Although the incidence of receptor positive tissue was lower in the central portions, the concentration of receptor within receptor-positive cells from either the central or peripheral portions was statistically indistinguishable. The apparent increase in loss of receptor from the central portion is unlikely to be due to cell necrosis since (a) obviously necrotic areas were removed before assay, and (b) pathology of the adjacent section was checked carefully during the determination of cellularity.
Intratumoral variations in receptor content
Relation of receptor distribution to clinical progress Only those patients for whom full FIGO classification (UICC-TNM, 1974) was possible, were included in the follow-up study. However, this sub-group of 51 patients was identical to the original 72 in terms of distribution between the various receptor classes (49% (+ +) in both cases, 33% instead of 32% in the (--) group and 17% instead of 18% in the (+ -) group). The division by menopausal status (4 pre-menopausal, 13 early post-menopausal and 34 more than 7 yr post-menopausal) was also similar, although the premenopausal group is now too small for further analysis.
The clinical follow-up of the 51 patients is shown in Table  III (Leake et al., 1979) but even receptor status can vary from positive to negative across individual tumours (Figure 1) . The follow-up of the patients (Table III) indicates the possible clinical significance of a heterogenous receptor distribution across a tumour. Clinically, it is not easy to determine whether an advanced local tumour is slow growing or aggressive. Multiple biopsies of such a tumour for determination of functional receptor status may be useful. Those tumours which are receptor positive throughout, reflect a relatively good prognosis, whereas variation in receptor status across the tumour may be associated with poor prognosis. In conclusion, assay of functional receptors (measured as soluble and tightly bound receptor in the homogenate) from different parts of large endometrial cancers may be a measure of both hormone sensitivity and prognosis.
Antibodies to oestrogen receptor have the potential to reveal the extent of heterogeneity of receptor distribution in any tumour (Crawford et al., 1985; King et al., 1985) . However, until their value has been fully assessed, the biochemical approach, described here, remains the best way to detect heterogeneous tumours. The optimal therapy for tumours heterogeneous in receptor status may well differ from that for homogeneous receptor positive tumour in that some combination or, rather, sequence of endocrine and chemotherapy may be more appropriate for the former type of tumour.
